IEX •
Healthcare •
Biotechnology •
Quote as of 08/19/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization4,865.91 mln
Float128 mln
Earnings Date11/11/2026
EPS
2.23
Solid
P / E
13.56
Fair value
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-1.25
Manipulation likely
Relative Strength
78
/ 100
Strongly outperforming
Debt / Equity
0.06
Debt-free
Business Description
ACADIA Pharmaceuticals is a US-based drug development company focused on treatments for brain-related and rare diseases. Its two approved products, NUPLAZID and DAYBUE, address psychosis linked to Parkinson's disease and the symptoms of Rett syndrome, respectively. The company also has a broad pipeline of experimental treatments in various stages of clinical testing, targeting conditions such as Alzheimer's disease psychosis, depression, essential tremor, and several rare genetic disorders. Founded in 1993 and based in San Diego, California, ACADIA works with partners including Neuren Pharmaceuticals and Stoke Therapeutics to expand its range of potential medicines.
